Why Market Access Has to Start Earlier in Clinical Development - Voices of SCOPE скачать в хорошем качестве

Why Market Access Has to Start Earlier in Clinical Development - Voices of SCOPE

n this Voices of SCOPE conversation, I sat down with Dr. Mei Yang, Co-Founder of NouStarX, to talk about where clinical development and market access still miss each other. Mei shares why reimbursement, pricing, and HTA considerations cannot wait until after Phase 3, especially in today’s global environment with very different payer expectations across the US and EU. We also get into execution. Even when strategy is aligned, small gaps in trial design, data collection, and operational planning can lead to costly amendments and delays. Her message is clear: bring clinical operations into the room earlier and design trials with market access in mind from the start. #VoicesOfSCOPE #SCOPEsummit #ClinicalResearch #MarketAccess #PricingAndReimbursement #ClinicalOperations #Biopharma #LifeSciences #HTA __________________________________________________________________________ Join the SCOPE 365 Community & Stay Informed about the Entire Clinical Trials Industry! 📰 Clinical Research News Online: https://bit.ly/4ndSLTa 🎟️ SCOPE Summit: https://bit.ly/3JJtJNf 🎫 SCOPE Summit Europe: https://bit.ly/45OHhjh 🤝 ClinEco - Clinical Trials Ecosystem & Marketplace: https://bit.ly/47KxsnR 🔗 SCOPE 365 LinkedIn Community: https://bit.ly/3VyhoOw